InVivoMAb大鼠IgG2a同种型对照：专用于三硝基苯酚免疫反应性研究

2A3单克隆抗体与三硝基苯酚反应。由于哺乳动物不表达三硝基苯酚，这种抗体非常适合在大多数体内和体外应用中用作大鼠IgG2a抗体的同种型匹配对照。

艾美捷InVivoMAb大鼠IgG2a同种型对照，抗三硝基苯酚：

货号：BXC-BE0089

亚型：大鼠IgG2a，κ

由LAL凝胶凝固测定法确定

推荐稀释液：InVivoPure pH 6.5稀释液

偶联：未偶联。提供抗体偶联服务。

配方：PBS，pH 6.5

不含稳定剂或防腐剂

内毒素：<2EU/毫克（<0.002EU/微克）

由LAL凝胶凝固测定法确定

纯度：>95%

由SDS-PAGE确定

无菌性：0.2微米过滤

在无动物设施中从细胞培养上清液中纯化

纯化：蛋白质G

分子量：150 kDa

储存：抗体溶液应以原始浓度在4°C下储存。不要冷冻。

InVivoMAb大鼠IgG2a同种型对照文献参考：

Bauche, D., et al. (2018). "LAG3(+) Regulatory T Cells Restrain Interleukin-23-Producing CX3CR1(+) Gut-Resident Macrophages during Group 3 Innate Lymphoid Cell-Driven Colitis" Immunity 49(2): 342-352 e345.

Ngiow, S. F., et al. (2015). "A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1" Cancer Res 75(18): 3800-3811.

Dai, M., et al. (2015). "Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies" Clin Cancer Res 21(5): 1127-1138.

Kurtulus, S., et al. (2015). "TIGIT predominantly regulates the immune response via regulatory T cells" J Clin Invest. doi : 10.1172/JCI81187.

Ellis, G. T., et al. (2015). "TRAIL+ monocytes and monocyte-related cells cause lung damage and thereby increase susceptibility to influenza-Streptococcus pneumoniae coinfection" EMBO Rep 16(9): 1203-1218.

Walsh, K. B., et al. (2014). "Animal model of respiratory syncytial virus: CD8+ T cells cause a cytokine storm that is chemically tractable by sphingosine-1-phosphate 1 receptor agonist therapy" J Virol 88(11): 6281-6293.